Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

V-006

Supelco

Valproic acid solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Sélectionner une taille de conditionnement

1 ML
132.00 CHF

132.00 CHF

Date d'expédition estimée le16 avril 2025

Devis pour commande en gros
Toutes les photos(1)

Sélectionner une taille de conditionnement

Changer de vue
1 ML
132.00 CHF

About This Item

Formule empirique (notation de Hill):
C8H16O2
Numéro CAS:
99-66-1
Poids moléculaire :
144.21
Numéro CE :
200-659-6
Numéro MDL:
MFCD00002672
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

132.00 CHF

Date d'expédition estimée le16 avril 2025

Devis pour commande en gros

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

CCCC(CCC)C(O)=O

InChI

1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

Clé InChI

NIJJYAXOARWZEE-UHFFFAOYSA-N

Informations sur le gène

human ... ALDH5A1(7915)

Description générale

A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, prescription monitoring or pharmaceutical research. Valproic acid, sold under trade names including Depakote®, Valparin, or Stavzor®, is an antiepileptic drug and mood stabilizer. The drug is prescribed for treatment of epilepsy, bipolar disorder, migraine headaches, and depression.

Application


  • The prenatal use of agmatine prevents social behavior deficits in VPA-exposed mice by activating the ERK/CREB/BDNF signaling pathway: This study explores the neuroprotective effects of agmatine against Valproic acid-induced behavioral deficits in mice, highlighting Valproic acid′s role in epigenetic modifications and its potential use in developmental neurotoxicology research (Chen et al., 2024).


Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Depakote is a registered trademark of Sanofi S.A.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Stavzor is a registered trademark of Noven Therapeutics, LLC

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Xiaolei Yin et al.
Nature methods, 11(1), 106-112 (2013-12-03)
Although Lgr5(+) intestinal stem cells have been expanded in vitro as organoids, homogeneous culture of these cells has not been possible thus far. Here we show that two small molecules, CHIR99021 and valproic acid, synergistically maintain self-renewal of mouse Lgr5(+)
Jakob Christensen et al.
JAMA, 309(16), 1696-1703 (2013-04-25)
Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential. However, prenatal exposure to valproate may increase the risk of autism. To determine whether prenatal exposure
Taylor Chomiak et al.
Neurotoxicology and teratology, 36, 57-66 (2012-09-13)
Autism spectrum disorder (ASD) is a behaviourally defined brain disorder affecting approximately 1 in 88 children. Many pathological studies have shown that ASD is frequently associated with grey and white matter changes that can be described by their deviations from
S Eyal et al.
British journal of pharmacology, 149(3), 250-260 (2006-08-09)
The antiepileptic drug valproic acid, a histone deacetylase (HDAC) inhibitor, is currently being tested as an anticancer agent. However, HDAC inhibitors may interact with anticancer drugs through induction of P-glycoprotein (P-gp, MDR1) expression. In this study we assessed whether valproic
P C Ho et al.
The pharmacogenomics journal, 3(6), 335-342 (2003-11-05)
The present study investigated the effect of cytochrome P450 2C9 (CYP2C9) genetic polymorphism on the biotransformation of valproic acid (VPA) to its hepatotoxic metabolite, 4-ene-VPA, and compared that to the formation of the inactive 4-OH-VPA and 5-OH-VPA. cDNA-expressed CYP2C9(*)2 and
Afficher tous les articles scientifiques apparentés

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique